Cytel的动态

??? We're going LIVE in 30 minutes to discuss Multi-Omic Strategies for Oncology Drug Development ?? Drop what you're doing and join Matthew Alderdice, Dr Craig Davison and Gerard Loughran as they share ways to enhance multi-omic data analysis, optimize oncology clinical trial outcomes, and accelerate time-to-market. ?? Can't make it? No problem! Sign up to watch on-demand for when you have the time: https://lnkd.in/enTSp2gV #AI #MultiOmics #Oncology #Webinar #PrecisionMedicine #Sonrai #SonraiDiscovery #Cloud #Biotech #Pharma #DrugDevelopment

The 5th Cytokine-Based Drug Development Summit is almost upon us and we couldn’t be more pleased for our expert Cytokine team to be in attendance! Harvey Dennis, our expert Account Lead, is preparing to set the scene on Day 1 with a review of the cytokine therapeutics landscape and address the important question, Where Are We Now? Access the full presentation details here. ?? https://ter.li/llav05 As we receive more clinical read-outs from leading IL-2 and IL-12 therapeutic developers, there has never been a better time to join our peers and accelerate your programs into the clinic. #cytokine #cytokines #cytokinedrugdevelopment #research #oncology #drugdevelopment

Available for ESMO 2024 Support! As we gear up for ESMO 2024, I’m available to provide strategic insights and competitive intelligence support. Whether you need help with post-conference analysis, or timely reporting, I’m here to assist. Feel free to message me directly or schedule a quick call to explore how I can support your ESMO 2024 efforts. #ESMO2024 #CompetitiveIntelligence #Pharma #Oncology #StrategicInsights

?? Join our webinar tomorrow: Multi-Omic Cloud Strategies for Accelerated Oncology Drug Development ??? We're going live at 11 am EST | 4 pm GMT You can still register to watch our experts Dr Craig Davison, Gerard Loughran and Matthew Alderdice discuss how AI and cloud-based platforms are revolutionizing multi-omic oncology research. Learn how to enhance data analysis, optimize oncology trials, and speed up time-to-market. ?? Register to join live or watch on-demand: https://lnkd.in/enTSp2gV #AI #MultiOmics #Oncology #Cloud #AI #MachineLearning #DrugDevelopment #Biotech #Pharma #Sonrai #SonraiDiscovery

#Oncology represents the largest segment in the #BioPharma industry, generating over $200 billion annually. Here's a quick peek at who's leading the pack after the first quarter of 2024 ?? #PharmaData #BioPharmaData #BioPharmaMarket #PharmaIndustry

Araris Biotech AG, with its proprietary conjugation technology and linker-payload platforms to efficiently develop and advance next-generation ADCs, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Araris' drug attachment is simple, site-specific and has the potential to stably accommodate various drug-load combinations without altering the pharmacokinetic profile of the antibody, resulting in ADCs with a high therapeutic window. Why is Araris Biotech a company to watch??? ?? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma?#companiestowatch

?? We’re delighted to share our latest collaborative research with Astellas Pharma. ?? ??Our joint publication highlights the tangible benefits of applying modelling and simulation to streamline drug development. Specifically, it showcases how our Virtual Tumour platform was used to inform the first-in-human clinical trial design by guiding the optimal dose and regimen selection for a novel immunotherapy combination. Our research highlights the value of predictive technologies across the drug development journey, from early discovery through to clinical trials, helping to accelerate progress while aiming to improve patient outcomes. Check out the full article ?? https://lnkd.in/e6Hzhv_u #DrugDevelopment #Oncology #Immunotherapy #ModelInformedDrugDevelopment #VirtualTumour

?? Biotech News: Pyxis Oncology ADC Trial Results Impact Market TL;DR: ?? Pyxis Oncology experiences significant stock decline following underwhelming initial results from their solid tumor ADC trials. ?? Key Implications: ? Market reaction underscores volatility in ADC investments ? Highlights critical importance of robust clinical data ? May influence broader ADC technology sentiment ?? Strategic Takeaways for Biotech Leaders: ? Monitor ADC landscape developments closely ? Implement rigorous trial design protocols ? Maintain transparent milestone communication ? Consider R&D portfolio diversification What are your thoughts on the future of ADC technologies in oncology? Share your insights below. #BiotechNews #Oncology #DrugDevelopment #ClinicalTrials #ADC #pharma #biotech #medicinetomarket

At Physiomics plc, we're proud to partner with leading biotech and pharma companies to bring innovative oncology solutions to life. Our expertise in PK/PD modelling and data analysis helps our clients achieve a deeper, more quantitative understanding of their novel molecules. But don't just take our word for it! Here’s what one of our clients has to say ?? We’re dedicated to helping you turn complex data into actionable insights, ensuring your projects move forward with confidence. Ready to elevate your drug development process? Let’s chat! #Cancer #DrugDevelopment #CancerDrugs #CancerSimulation #CombinationTherapies #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #TranslationalModelling #PYC